Sufentanil conversion reference
Check OpioidCalc's OME factors by route, then open the formulation-specific pharmacology, cautions and supporting sources.
Educational reference for qualified healthcare professionals. Conversion factors estimate oral morphine equivalent daily dose. They are not a recommended switching dose. Confirm the result with a current source and local guidance.
Free download · iOS and Android · Optional Pro features
Current OpioidCalc factors
Multiply the dose or delivery rate in the stated units by the factor to estimate mg oral morphine equivalent per day. These are the factors currently used by OpioidCalc. Methadone uses 4.7 when converting methadone to OME.
| Route | Input units | OME factor |
|---|---|---|
| Parenteral | mcg/day | 2 |
Compare a complete regimen in the app
Formulations and cautions
Choose a formulation to read its pharmacology, population, limitations and source references.
ParenteralDefault in appIntravenous injection
App source review: 27 August 2026
View details and sources
Intravenous injection
App source review: 27 August 2026
View details and sources- Elimination half-life
- Adult terminal elimination half-life approximately 164 minutes
Population: Adults receiving intravenous sufentanil
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Sufentanil citrate injection prescribing information12.3 Pharmacokinetics. United States. Source revised 1 June 2026. App review 27 August 2026. Regulatory product information.
- Population effects
- Reported terminal half-life is shorter in infants and children and longer in neonates than in adults.
Population: Adults, infants, children and neonates
Applicability: United States
- Limitation: Age-stratified values come from different small studies and should not be merged.
- Sufentanil citrate injection prescribing information12.3 Pharmacokinetics. United States. Source revised 1 June 2026. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Full mu-opioid receptor agonist.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Sufentanil citrate injection prescribing information12.1 Mechanism of Action. United States. Source revised 1 June 2026. App review 27 August 2026. Regulatory product information.
- Metabolism
- Sufentanil is metabolised mainly in the liver and small intestine.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Sufentanil citrate injection prescribing information12.3 Pharmacokinetics. United States. Source revised 1 June 2026. App review 27 August 2026. Regulatory product information.
- Active metabolites
- No analgesically active metabolite is identified by the label.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Sufentanil citrate injection prescribing information12.3 Pharmacokinetics. United States. Source revised 1 June 2026. App review 27 August 2026. Regulatory product information.
- Elimination
- About 80% is excreted within 24 hours; about 2% is excreted unchanged.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Sufentanil citrate injection prescribing information12.3 Pharmacokinetics. United States. Source revised 1 June 2026. App review 27 August 2026. Regulatory product information.
ParenteralContinuous parenteral infusion
App source review: 27 August 2026
View details and sources
Continuous parenteral infusion
App source review: 27 August 2026
View details and sourcesSources used on this page
Other medicine references
Use the full calculator
Compare opioid regimens and inspect formulation-specific information in OpioidCalc for iOS and Android.